• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

阿尔托纳预后指数：一种用于非特殊类型雌激素受体阳性且人表皮生长因子受体2阴性乳腺癌的新预后指数。

Altona Prognostic Index: A New Prognostic Index for ER-Positive and Her2-Negative Breast Cancer of No Special Type.

作者信息

Wegscheider Anne-Sophie, Ulm Bernhard, Friedrichs Kay, Lindner Christoph, Niendorf Axel

机构信息

MVZ Prof. Dr. med. A. Niendorf Pathologie Hamburg-West GmbH Institut für Histologie, Zytologie und Molekulare Diagnostik, 22767 Hamburg, Germany.

Unabhängige Statistische Beratung Bernhard Ulm, 80339 München, Germany.

出版信息

Cancers (Basel). 2021 Jul 28;13(15):3799. doi: 10.3390/cancers13153799.

DOI:10.3390/cancers13153799
PMID:34359699
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8345191/
Abstract

Breast cancer is a heterogeneous disease representing a number of different histopathologic and molecular types which should be taken into consideration if prognostic or predictive models are to be developed. The aim of the present study was to demonstrate the validity of the long-known Nottingham prognostic index (NPI) in a large retrospective study ( = 6654 women with a first primary unilateral and unifocal invasive breast cancer diagnosed and treated between April 1996 and October 2018; median follow-up time of breast cancer cases was 15.5 years [14.9-16.8]) from a single pathological institution. Furthermore, it was intended to develop an even superior risk stratification model considering an additional variable, namely the patient's age at the time of diagnosis. Heterogeneity of these cases was addressed by focusing on estrogen receptor-positive as well as Her2-negative cases and taking the WHO-defined different tumor types into account. Calculating progression free survival Cox-regression and CART-analysis revealed significantly superior iAUC as well as concordance values in comparison to the NPI based stratification, leading to an alternative, namely the Altona prognostic index (API). The importance of the histopathological tumor type was corroborated by the fact that when calculated separately and in contrast to the most frequent so-called "No Special Type" (NST) carcinomas, neither NPI nor API could show valid prognostic stratification.

摘要

乳腺癌是一种异质性疾病，包含多种不同的组织病理学和分子类型。如果要开发预后或预测模型，就需要考虑这些因素。本研究的目的是在一项大型回顾性研究中（研究对象为1996年4月至2018年10月期间确诊并接受治疗的6654例首次原发性单侧单灶浸润性乳腺癌女性患者；乳腺癌病例的中位随访时间为15.5年[14.9 - 16.8]），验证早已为人所知的诺丁汉预后指数（NPI）的有效性。此外，本研究旨在开发一个更优的风险分层模型，该模型考虑了一个额外变量，即患者诊断时的年龄。通过聚焦雌激素受体阳性以及人表皮生长因子受体2（Her2）阴性病例，并考虑世界卫生组织定义的不同肿瘤类型，解决了这些病例的异质性问题。计算无进展生存期的Cox回归和CART分析显示，与基于NPI的分层相比，iAUC和一致性值显著更优，从而得出了一个替代方案，即阿尔托纳预后指数（API）。组织病理学肿瘤类型的重要性得到了以下事实的证实：与最常见的所谓“非特殊类型”（NST）癌相比，单独计算时，NPI和API均无法显示有效的预后分层。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e40/8345191/ec6ed6cd6370/cancers-13-03799-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e40/8345191/3d0b370eeb90/cancers-13-03799-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e40/8345191/92dcf75b058a/cancers-13-03799-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e40/8345191/6d5222fd571a/cancers-13-03799-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e40/8345191/0138e751f4c3/cancers-13-03799-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e40/8345191/ec6ed6cd6370/cancers-13-03799-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e40/8345191/3d0b370eeb90/cancers-13-03799-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e40/8345191/92dcf75b058a/cancers-13-03799-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e40/8345191/6d5222fd571a/cancers-13-03799-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e40/8345191/0138e751f4c3/cancers-13-03799-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e40/8345191/ec6ed6cd6370/cancers-13-03799-g005.jpg

相似文献

1
Altona Prognostic Index: A New Prognostic Index for ER-Positive and Her2-Negative Breast Cancer of No Special Type.阿尔托纳预后指数：一种用于非特殊类型雌激素受体阳性且人表皮生长因子受体2阴性乳腺癌的新预后指数。
Cancers (Basel). 2021 Jul 28;13(15):3799. doi: 10.3390/cancers13153799.
2
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
3
Prognostic contribution of mammographic breast density and HER2 overexpression to the Nottingham Prognostic Index in patients with invasive breast cancer.乳腺钼靶密度和HER2过表达对浸润性乳腺癌患者诺丁汉预后指数的预后贡献。
BMC Cancer. 2016 Nov 2;16(1):833. doi: 10.1186/s12885-016-2892-y.
4
Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis.乳腺癌诊断后 5 年内，孕激素受体和 HER2 的定性评估可使诺丁汉预后指数提高。
J Clin Oncol. 2010 Sep 20;28(27):4129-34. doi: 10.1200/JCO.2009.26.4200. Epub 2010 Aug 16.
5
Overview of resistance to systemic therapy in patients with breast cancer.乳腺癌患者全身治疗耐药概述。
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.
6
Development and validation of a new predictive model for breast cancer survival in New Zealand and comparison to the Nottingham prognostic index.开发和验证新西兰乳腺癌生存的新预测模型，并与诺丁汉预后指数进行比较。
BMC Cancer. 2018 Sep 17;18(1):897. doi: 10.1186/s12885-018-4791-x.
7
Determination of GP88 (progranulin) expression in breast tumor biopsies improves the risk predictive value of the Nottingham Prognostic Index.测定乳腺肿瘤活检中GP88（颗粒体蛋白前体）的表达可提高诺丁汉预后指数的风险预测价值。
Diagn Pathol. 2016 Aug 8;11(1):71. doi: 10.1186/s13000-016-0520-4.
8
The Impact of EndoPredict Clinical Score on Chemotherapy Recommendations in Women with Invasive ER/HER2 Breast Cancer Stratified as Having Moderate or Poor Prognosis by Nottingham Prognostic Index.根据诺丁汉预后指数分层为中度或预后不良的浸润性ER/HER2乳腺癌女性患者中，EndoPredict临床评分对化疗推荐的影响。
Anticancer Res. 2018 Aug;38(8):4747-4752. doi: 10.21873/anticanres.12782.
9
Correlation analysis between molecular subtypes and Nottingham Prognostic Index in breast cancer.乳腺癌分子亚型与诺丁汉预后指数的相关性分析
Oncotarget. 2017 May 27;8(43):74096-74105. doi: 10.18632/oncotarget.18242. eCollection 2017 Sep 26.
10
A comparative analysis of recurrence risk predictions in ER+/HER2- early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast.使用 NHS 诺丁汉预后指数、PREDICT 和 CanAssist Breast 对 ER+/HER2- 早期乳腺癌的复发风险预测进行比较分析。
Breast Cancer Res Treat. 2022 Nov;196(2):299-310. doi: 10.1007/s10549-022-06729-7. Epub 2022 Sep 10.

引用本文的文献

1
CD301 and LSECtin glycan-binding receptors of innate immune cells serve as prognostic markers and potential predictors of immune response in breast cancer subtypes.先天免疫细胞的 CD301 和 LSECtin 糖结合受体可作为乳腺癌亚型的预后标志物和免疫反应的潜在预测指标。
Glycobiology. 2024 Apr 1;34(3). doi: 10.1093/glycob/cwae003.
2
Re-evaluation of publicly available gene-expression databases using machine-learning yields a maximum prognostic power in breast cancer.使用机器学习对公开可用的基因表达数据库进行重新评估可在乳腺癌中产生最大的预后能力。
Sci Rep. 2023 Oct 5;13(1):16402. doi: 10.1038/s41598-023-41090-9.
3
Development and validation of an extended Cox prognostic model for patients with ER/PR+ and HER2- breast cancer: a retrospective cohort study.

本文引用的文献

1
Breast Cancer in Patients 80 Years-Old and Older.80岁及以上患者的乳腺癌
Eur J Breast Health. 2020 May 21;16(3):208-212. doi: 10.5152/ejbh.2020.5659. eCollection 2020 Jul.
2
Adjuvant and neoadjuvant therapy for breast cancer.乳腺癌的辅助和新辅助治疗。
Jpn J Clin Oncol. 2020 Mar 9;50(3):225-229. doi: 10.1093/jjco/hyz213.
3
Outcome of patients with breast cancer in the oldest old (≥80 years).超高龄（≥80 岁）乳腺癌患者的预后。
ER/PR+ 和 HER2- 乳腺癌患者扩展 Cox 预后模型的建立与验证：一项回顾性队列研究。
World J Surg Oncol. 2022 Oct 12;20(1):338. doi: 10.1186/s12957-022-02790-0.
Eur J Obstet Gynecol Reprod Biol. 2020 Jan;244:66-70. doi: 10.1016/j.ejogrb.2019.11.009. Epub 2019 Nov 13.
4
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.在接受辅助内分泌治疗加化疗或单纯内分泌治疗的乳腺癌患者中，EndoPredict 预测化疗获益。
Breast Cancer Res Treat. 2019 Jul;176(2):377-386. doi: 10.1007/s10549-019-05226-8. Epub 2019 Apr 30.
5
Prognostic models for breast cancer: a systematic review.乳腺癌预后模型：系统评价。
BMC Cancer. 2019 Mar 14;19(1):230. doi: 10.1186/s12885-019-5442-6.
6
Mastectomy or Breast-Conserving Therapy for Early Breast Cancer in Real-Life Clinical Practice: Outcome Comparison of 7565 Cases.现实临床实践中早期乳腺癌的乳房切除术或保乳治疗：7565例病例的结果比较
Cancers (Basel). 2019 Jan 31;11(2):160. doi: 10.3390/cancers11020160.
7
Development and validation of a new predictive model for breast cancer survival in New Zealand and comparison to the Nottingham prognostic index.开发和验证新西兰乳腺癌生存的新预测模型，并与诺丁汉预后指数进行比较。
BMC Cancer. 2018 Sep 17;18(1):897. doi: 10.1186/s12885-018-4791-x.
8
Survival estimates stratified by the Nottingham Prognostic Index for early breast cancer: a systematic review and meta-analysis of observational studies.早期乳腺癌诺丁汉预后指数分层的生存估计：观察性研究的系统评价和荟萃分析。
Syst Rev. 2018 Sep 15;7(1):142. doi: 10.1186/s13643-018-0803-9.
9
Breast Cancer in the Elderly.老年人乳腺癌。
Surg Clin North Am. 2018 Aug;98(4):819-833. doi: 10.1016/j.suc.2018.04.002. Epub 2018 May 21.
10
Breast cancer: The translation of big genomic data to cancer precision medicine.乳腺癌：大型基因组数据向癌症精准医学的转化。
Cancer Sci. 2018 Mar;109(3):497-506. doi: 10.1111/cas.13463. Epub 2017 Dec 30.